Obalon Therapeutics, Inc.

Fourth quarter 2019 revenue was $786,000, compared with $333,000 in the prior quarter as stated on the call. Gross profit was $238,000 versus a gross deficit of $79,000 in Q3 2019, while net loss was $4.9 million, or $0.64 per share, compared with a net loss of $3.7 million, or $0.61 per share. Full-year 2019 revenue was approximately $3.3 million versus $9.1 million in 2018; gross profit was $331,000 with a 10% gross margin versus about $3.7 million and 40% in 2018; operating loss was about $23.2 million versus $37.0 million; and net loss was $23.7 million, or $5.03 per share, versus $37.4 million, or $19.64 per share. For the treatment center model, management said about $140,000 of revenue was recognized in Q4 while cash collected was almost $350,000. Guidance/targets: management aims for five to eight operational sites by year-end 2020, average steady-state new patient volume of 15 to 30 per center per month, and average net revenue recognized per patient of $5,000 to $6,000 over a 12-month treatment term. The company ended Q4 with $14.9 million in cash and cash equivalents and short-term investments and no debt.

Bill Plovanic emphasized that the first company-managed center is validating the idea of a standardized, repeatable retail treatment model for Obalon’s balloon system. He said the company can now measure the full patient funnel, from digital advertising to booked consultations to treatment conversion, and that the first and second centers have produced encouraging early results with only minor operational changes needed so far. His tone was optimistic but measured, repeatedly noting that the model is still early and that the company is focusing on expansion, marketing efficiency, and access for the estimated 69 million U.S. adults who qualify for the FDA-indicated BMI range.

Nooshin Hussainy walked through the quarter’s financials and highlighted the mix of revenue from the new center model, U.S. physician customers, and international distributors. She said Q4 revenue was $786,000, with about $140,000 recognized from the retail treatment center model but almost $350,000 collected in cash, reflecting the upfront-payment/over-time-revenue recognition mismatch. She also noted gross profit of $238,000, R&D of about $1.5 million, SG&A of $3.643 million, operating loss of about $5.0 million, and net loss of about $4.9 million. On capital allocation, she said the Lincoln Park equity line could provide up to $16 million over 36 months to fund expansion, that it has no warrants or covenants, and that Obalon had $14.9 million in cash and short-term investments and no debt at quarter-end.

Analysts focused on the treatment center ramp, asking about patient conversion rates, what had been learned from the first center, and whether capacity could support more patients as the network scales. Management said it is tracking the full funnel closely, has been “very pleased” with several metrics, and sees only minor changes needed so far; Bill added that current peak capacity is above the company’s current monthly new-patient goals and that staffing and hours can be adjusted if demand increases. Another question addressed international revenue; management said the Qatar distributor is a familiar counterpart under a one-year agreement and revenue should be similar quarter to quarter, though perhaps somewhat lower over time.